TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Study of Different Pain Scores in Single Transumbilical Incision Laparoscopic Cholecystectomy Versus Classic Laparoscopic Cholecystectomy
Brief Summary: The attempt to further reduce the operative trauma in laparoscopic cholecystectomy led in new techniques, as Natural Orifice Transluminal Endoscopic Surgery (NOTES) and Single Incision Laparoscopic Surgery (SILS). These new techniques are considered as painless procedures, but there are not any publications to study a possible different pain score in new techniques versus classic laparoscopic cholecystectomy. In this randomized controlled study the researchers have investigated the pain scores, the incidence of nausea and vomiting and analgesics request after the procedure.


Options:
A: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SILS cholecystectomy | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TPCL cholecystectomy | Intervention Type: PROCEDURE; Name: SILS cholecystectomy; Assigned to Arm(s): Group 1 | Intervention Type: PROCEDURE; Name: TPCL cholecystectomy; Assigned to Arm(s): Group 2
B: Arm Label: Laparoscopic Cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Cholecystectomy | Arm Label: SILS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SILS | Intervention Type: PROCEDURE; Name: Laparoscopic Cholecystectomy; Assigned to Arm(s): Laparoscopic Cholecystectomy | Intervention Type: PROCEDURE; Name: SILS; Assigned to Arm(s): SILS
C: Arm Label: SILS appendectomy; Type: EXPERIMENTAL; Interventions: Procedure: SILS appendectomy | Arm Label: Conventional laparoscopic appendectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional laparoscopic appendectomy | Intervention Type: PROCEDURE; Name: SILS appendectomy; Assigned to Arm(s): SILS appendectomy | Intervention Type: PROCEDURE; Name: conventional laparoscopic appendectomy; Assigned to Arm(s): Conventional laparoscopic appendectomy
D: Arm Label: SIL-V; Type: ACTIVE_COMPARATOR; Interventions: Procedure: single incision laparoscopic varicocelectomy | Arm Label: CTL-V; Type: ACTIVE_COMPARATOR; Interventions: Procedure: conventional transperitoneal laparoscopic varicocelectomy | Intervention Type: PROCEDURE; Name: single incision laparoscopic varicocelectomy; Assigned to Arm(s): SIL-V | Intervention Type: PROCEDURE; Name: conventional transperitoneal laparoscopic varicocelectomy; Assigned to Arm(s): CTL-V

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Study of Regenerative Cell Therapy in Treating Diabetic Patients With Critical Limb Ischemia
Brief Summary: The aim of this study is to assess the efficacy and safety of autologous transplantation of bone-marrow cells for therapeutic angiogenesis and vasculogenesis in diabetic patients with non-revascularizable critical limb ischemia.


Options:
A: Arm Label: Allogeneic Mesenchymal Stromal Cell; Type: EXPERIMENTAL; Interventions: Drug: Allogeneic Mesenchymal Stromal Cell | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Allogeneic Mesenchymal Stromal Cell; Assigned to Arm(s): Allogeneic Mesenchymal Stromal Cell | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
C: Arm Label: Autologous Bone Marrow Mononuclear Cells; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells; Assigned to Arm(s): Autologous Bone Marrow Mononuclear Cells
D: Arm Label: MultiGeneAngio; Type: EXPERIMENTAL; Interventions: Biological: MultiGeneAngio | Intervention Type: BIOLOGICAL; Name: MultiGeneAngio; Assigned to Arm(s): MultiGeneAngio

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial
Brief Summary: The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.


Options:
A: Arm Label: Baseline period; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Uterine balloon tamponade; Type: EXPERIMENTAL; Interventions: Other: Uterine balloon tamponade | Intervention Type: OTHER; Name: Uterine balloon tamponade; Assigned to Arm(s): Uterine balloon tamponade
B: Arm Label: Bakri Balloon with abdominal traction stitch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal traction stitch, Device: Bakri Balloon | Arm Label: Bakri Balloon without abdominal traction stitch; Type: EXPERIMENTAL; Interventions: Device: Bakri Balloon | Intervention Type: PROCEDURE; Name: Abdominal traction stitch; Assigned to Arm(s): Bakri Balloon with abdominal traction stitch | Intervention Type: DEVICE; Name: Bakri Balloon; Assigned to Arm(s): Bakri Balloon with abdominal traction stitch, Bakri Balloon without abdominal traction stitch
C: Arm Label: Amr Maneuver; Type: EXPERIMENTAL; Interventions: Procedure: Amr maneuver | Arm Label: Active management alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Amr maneuver; Assigned to Arm(s): Amr Maneuver
D: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial
Brief Summary: The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
B: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
C: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial
Brief Summary: The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.


Options:
A: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
B: Arm Label: Coagulation factor concentrates; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate | Arm Label: Fresh Frozen Plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh Frozen Plasma blood type 0, A, B and AB | Intervention Type: DRUG; Name: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate; Assigned to Arm(s): Coagulation factor concentrates | Intervention Type: DRUG; Name: Fresh Frozen Plasma blood type 0, A, B and AB; Assigned to Arm(s): Fresh Frozen Plasma
C: Arm Label: fibrinogen concentrate-treated group; Type: EXPERIMENTAL; Interventions: Drug: fibrinogen concentrate | Arm Label: non-fibrinogen concentrate-treated group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fibrinogen concentrate; Assigned to Arm(s): fibrinogen concentrate-treated group
D: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial
Brief Summary: The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.


Options:
A: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
D: Arm Label: Standard care for post-partum hemorrhage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Care | Arm Label: rFVIIa; Type: EXPERIMENTAL; Interventions: Drug: rFVIIa | Intervention Type: DRUG; Name: rFVIIa; Assigned to Arm(s): rFVIIa | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): Standard care for post-partum hemorrhage

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial
Brief Summary: The WOMAN trial is a large pragmatic randomised double-blind, placebo controlled trial to quantify the effects of the early administration of tranexamic acid on death, hysterectomy and other relevant outcomes. 20,000 adult women, after delivery who have clinically diagnosed postpartum haemorrhage, are eligible if the responsible doctor is for any reason substantially uncertain whether or not to use an antifibrinolytic agent. Additionally, TWO nested studies will be conducted in a subset of women trial participants. The first nested study (ETAC) aims to evaluate the effect of tranexamic acid (TXA) on markers of coagulation in 400 women randomised to the WOMAN trial. The second nested study (ETAPLAT) aims to evaluate the haemostatic effect and antithrombotic effect of TXA in 128 women randomised to the WOMAN trial.


Options:
A: Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid Injectable Solution | Arm Label: Chloride solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic Acid Injectable Solution; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): Chloride solution
B: Arm Label: Tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo [Saline] | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Placebo [Saline]; Assigned to Arm(s): placebo
C: Arm Label: Tranexamic Acid (TXA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo (0.9% normal saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Saline) | Arm Label: Hypotension-avoidance strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Perioperative hypotension-avoidance strategy | Arm Label: Perioperative hypertension-avoidance strategy; Type: PLACEBO_COMPARATOR; Interventions: Other: Perioperative hypertension-avoidance strategy | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid (TXA) | Intervention Type: DRUG; Name: Placebo (Saline); Assigned to Arm(s): Placebo (0.9% normal saline) | Intervention Type: OTHER; Name: Perioperative hypotension-avoidance strategy; Assigned to Arm(s): Hypotension-avoidance strategy | Intervention Type: OTHER; Name: Perioperative hypertension-avoidance strategy; Assigned to Arm(s): Perioperative hypertension-avoidance strategy
D: Arm Label: TXA; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): TXA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Brief Summary: The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Intranasal Oxytocin (Syntocinon); Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Intranasal Oxytocin (Syntocinon) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Brief Summary: The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Brief Summary: The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.


Options:
A: Intervention Type: DRUG; Name: secretin, synthetic porcine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: secretin, biologically derived porcine; Assigned to Arm(s): N/A
B: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine Hydrochloride; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients With Autism
Brief Summary: The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.


Options:
A: Arm Label: Memantine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine - Extended Release (ER) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Memantine - Extended Release (ER); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Memantine 1; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Memantine 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine Hydrochloride (HCl) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo capsules | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 1 | Intervention Type: DRUG; Name: Memantine Hydrochloride (HCl); Assigned to Arm(s): Memantine 2 | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Placebo
D: Arm Label: memantine; Type: EXPERIMENTAL; Interventions: Drug: memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: memantine; Assigned to Arm(s): memantine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B